TD Private Client Wealth LLC Purchases 150,601 Shares of Kenvue Inc. (NYSE:KVUE)

TD Private Client Wealth LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 116.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 279,728 shares of the company's stock after buying an additional 150,601 shares during the period. TD Private Client Wealth LLC's holdings in Kenvue were worth $5,972,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC grew its stake in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company's stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares during the last quarter. State Street Corp boosted its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares during the last quarter. Geode Capital Management LLC grew its position in Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock valued at $1,029,810,000 after purchasing an additional 399,846 shares during the last quarter. Finally, Harris Associates L P increased its stake in Kenvue by 7.5% during the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock valued at $727,658,000 after purchasing an additional 2,186,114 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Canaccord Genuity Group increased their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Barclays cut their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday, January 17th. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Finally, Evercore ISI started coverage on Kenvue in a research report on Monday. They issued an "in-line" rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $23.85.

Kenvue Price Performance

Shares of KVUE stock traded down $0.29 on Tuesday, hitting $23.08. 14,987,781 shares of the stock traded hands, compared to its average volume of 16,155,267. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a 50 day simple moving average of $22.13 and a two-hundred day simple moving average of $22.44. The firm has a market cap of $44.11 billion, a price-to-earnings ratio of 43.55, a PEG ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.55%. Kenvue's dividend payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.